Atorvastatin News
Volcano Participates In AstraZeneca Sponsored SATURN Clinical Trial
Monday morning, Volcano Corp. (VOLC), a manufacturer of a range of intravascular ultrasound, or IVUS, and functional measurement products, announced its participation in SATURN study. This marks the first major pharmaceutical...
Intensive Statin Therapy Prevents Repeat Cardiovascular Events in High-Risk Patients: Presented at EAS
High-dose lipid-lowering therapy with atorvastatin not only effectively prevents a first cardiovascular (CV) event from occurring compared with simvastatin, but it also continues to prevent a second, third, fourth, and even fifth...
Intensive Atorvastatin Effective in CKD Patients and Also Reduces Second and Third Cardiovascular Events
Analyses from two large "lower-is-better" cholesterol studies have provided additional support for intensive lipid lowering with high-dose atorvastatin (Lipitor, Pfizer). One analysis showed that aggressive statin therapy reduced...
Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study
Pfizer announced today that LipitorŪ (atorvastatin calcium) 80 mg showed unexpectedly potent reduction in myocardial ischemia (a condition defined by insufficient blood supply and oxygen to the heart) in patients with chronic...
Pfizer Yanks Jarvik Atorvastatin (Lipitor) Ads After Congressional Inquiry
Pfizer said today that it was pulling the plug on advertising that features Robert Jarvik, M.D., promoting the benefit of atorvastatin (Lipitor).